Karyopharm
FDA approves multiple myeloma therapy Xpovio despite safety concerns
July 4, 2019Sales and Marketing FDA, Karyopharm, Xpovio, multiple myeloma, pharma
The FDA has made the controversial decision to approve the nuclear export inhibitor Xpovio (selinexor) from Karyopharm Therapeutics, in combination …
Biogen announces acquisition along with financials, but it’s tiny
January 26, 2018Medical Communications, Sales and Marketing Biogen, Karyopharm, biotech, drugs, pharma, pharmaceutical
Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big …
Bad start to month for Karyopharm gets worse with clinical hold
March 13, 2017Sales and Marketing Karyopharm
Coming just over a week after Karyopharm Therapeutics had announced that its lead drug had failed in a Phase 2 …
Latest content
